Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · UFP Technologies (UFPT)

UFP Technologies reports 2024 net income up 31.3% to $59.0 million

Positive Impact 3 of 5 earnings Written later

UFP Technologies reported fourth-quarter and full-year 2024 results on February 25, 2025. Full-year net sales rose 26.1% to $504.4 million and GAAP diluted EPS was $7.58, compared with $5.83 in 2023, while fourth-quarter sales grew 41.9% to $144.1 million. Long-term debt, less current portion, was $176.9 million at December 31, 2024, up from $28.0 million a year earlier.

Key points

  • Full-year 2024 net income was $59.0 million, up 31.3% from $44.9 million; GAAP diluted EPS was $7.58 versus $5.83.
  • Fourth-quarter 2024 net sales were $144.1 million, up 41.9%; GAAP diluted EPS was $2.10 versus $1.51.
  • Full-year MedTech sales rose 30.2% to $450.8 million; gross margin was 29.1% versus 28.1%.
  • Long-term debt, less current portion, was $176.9 million at December 31, 2024, versus $28.0 million at December 31, 2023.

The filing

CompanyUFP Technologies (UFPT)
Form8-K, current report
Filed with the SECFeb 25, 2025, 4:10 PM ET
Accession number0001171843-25-001061

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 25, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.